Fang Xu
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
High expression of Tbx15 in lung adenocarcinoma cells facilitates bone metastasis by suppressing IL-25 secretion and reducing MVP expression in osteoclasts.
Journal: Toxicology and applied pharmacology
Published: March 16, 2026
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 22, 2025
Sugemalimab for Post-PD-1 Progression in Non-small Cell Lung Cancer.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: July 08, 2025
The crosstalk between lung adenocarcinoma cells and M2 macrophages promotes cancer cell development via the SFRS1/miR-708-5p/PD-L1 axis.
Journal: Life sciences
Published: January 07, 2025
Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study.
Journal: Therapeutic advances in medical oncology
Published: December 08, 2024
Neutrophil extracellular traps promote growth of lung adenocarcinoma by mediating the stability of m6A-mediated SLC2A3 mRNA-induced ferroptosis resistance and CD8(+) T cell inhibition.
Journal: Clinical and translational medicine
Published: August 13, 2024
Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
Journal: Journal of thoracic disease
Published: May 11, 2024
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 15, 2024
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
Journal: EClinicalMedicine
Published: October 13, 2023
Discovery of PRDM16-Mediated TRPA1 Induction as the Mechanism for Low Tubulo-Interstitial Fibrosis in Diabetic Kidney Disease.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 15, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Journal: British journal of cancer
Published: April 10, 2023
Last Updated: 09/26/2026